SERA
SERA PROGNOSTICS, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.02
+4.40%Nov 4, 2026, 21:05 UTC
Florida began Medicaid coverage for SERA PROGNOSTICS, INC.' PreTRM test with established fee schedule pricing.
Source:Nov 4, 2026, 21:05 UTC
SERA PROGNOSTICS, INC. reported third-quarter 2026 financial results and said PreTRM test volume rose 54% sequentially and approximately fivefold from the first quarter, while ordering providers increased 34% sequentially and approximately threefold.
Source:Oct 21, 2026, 20:05 UTC
SERA PROGNOSTICS, INC. announced that it will report its third-quarter fiscal 2026 financial results after market close on November 4, 2026, and host a conference call and live webcast at 5:00 p.m.
Source:Aug 19, 2026, 00:00 UTC
Sera Prognostics, Inc. announced the appointment of Scott Gleason as Chief Financial Officer and Treasurer, effective August 31, 2026.
Aug 13, 2026, 00:47 UTC
Sera Prognostics, Inc. held its Q2 2026 earnings call on August 12, 2026, discussing financial results and business updates.
Source:Aug 12, 2026, 22:21 UTC
Sera Prognostics, Inc. reported a second-quarter loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.14 loss and wider than the year-ago loss of $0.16 per share.
Source:Aug 12, 2026, 20:05 UTC
Sera Prognostics launched its fourth partnership program in August 2026, expanding implementation of PreTRM Test-guided care through a state-based initiative with a national payer.
Source:Jun 24, 2026, 20:05 UTC
Sera Prognostics participates in a multi-institutional research program awarded up to $10.4 million by ARPA-H to develop a point-of-care diagnostic test for safer birth.
Source:Jun 1, 2026, 20:05 UTC
Jeff Elliott notified Sera Prognostics of his intention to step down from its Board of Directors, effective June 4, 2026.
Source: